Evidence map›Paper›PMID 31130713›Full record

ArticleJournal of clinical medicine2019

Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients.

Mélanie Rinaudo-Gaujous, Vincent Blasco-Baque, Pierre Miossec, Philippe Gaudin, Pierre Farge, Xavier Roblin, Thierry Thomas, Stephane Paul, Hubert Marotte

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Towards Personalized Medicine in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Rheumatoid Arthritis-Associated Mechanisms ofJournal of clinical medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Mélanie Rinaudo-GaujousGIMAP EA3064, Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm Vaccinology, Hôpital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, France. melanie.rinaudogaujous@chpg.mc.
Vincent Blasco-BaqueInstitute of Cardiovascular and Metabolic Diseases, CHU Rangueil, 31400 Toulouse, France. vincent.blasco@inserm.fr.
Pierre MiossecClinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, CHU Lyon, 69003 Lyon, France. pierre.miossec@univ-lyon1.fr.
Philippe GaudinDepartment of Rheumatology, CHU Grenoble, 38130 Échirolles, France. pgaudin@chu-grenoble.fr.
Pierre FargeFaculty of Odontology, University Lyon I., 69622 Villeurbanne, France. pierre.farge@univ-lyon1.fr.
Xavier RoblinDepartment of Gastroenterology, Hôpital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, France. xavier.roblin@chu-st-etienne.fr.
Thierry ThomasDepartment of Rheumatology, Hôpital Nord, CHU Saint-Etienne, 42055 Saint-Etienne, France. thierry.thomas@chu-st-etienne.fr.
Stephane PaulGIMAP EA3064, Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm Vaccinology, Hôpital Nord, CHU Saint-Etienne, 42270 Saint-Priest-en-Jarez, France. stephane.paul@chu-st-etienne.fr.
Hubert MarotteDepartment of Rheumatology, Hôpital Nord, CHU Saint-Etienne, 42055 Saint-Etienne, France. hubert.marotte@chu-st-etienne.fr.ORCID 0000-0003-1177-9497
Université Claude Bernard Lyon 1 · FRCentre Hospitalier Universitaire de Grenoble · FRHôpital Edouard Herriot · FRHôpital Nord · FRInserm · FRInstitut des Maladies Métaboliques et Cardiovasculaires · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRheumatoid arthritis and periodontal disease are associated together, but the effect of therapy provided for one disease to the second one remained under-investigated. This study investigated effect of infliximab therapy used to treat rheumatoid arthritis (RA) on various biomarkers of periodontal disease (PD) severity including serologies of

methodsSeventy nine RA patients were enrolled at the time to start infliximab therapy and the 28 joint disease activity score (DAS28), anti-cyclic citrullinated petides 2nd generation (anti-CCP2), anti-

resultsAt baseline, anti-CCP2 titers were associated with anti-

conclusionMMP-3 level can be a useful marker of the efficacy of infliximab in RA patients. The treatment did not affect anti-

Indexed as

infliximabmatrix metalloproteinase 3periodontal diseasePorphyromonas gingivalisRheumatoid arthritis

Identifiers

PMID31130713
PMCPMC6571563
OpenAlexW2945757308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.